0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

1
Articles   |    
A+KIDS, a Web-Based Antipsychotic Registry for North Carolina Youths: An Alternative to Prior Authorization
Robert B. Christian, M.D.; Joel F. Farley, Ph.D.; Brian Sheitman, M.D.; Jerry R. McKee, Pharm.D.; David Wei, Ph.D.; John Diamond, M.D.; Alan Chrisman, M.D.; Larry Jarrett Barnhill, Jr., M.D.; Lynn Wegner, M.D.; Guy Palmes, M.D.; Troy Trygstad, Pharm.D., Ph.D.; Trista Pfeiffenberger, Pharm.D.; Steven E. Wegner, J.D., M.D.; Randell Best, M.D.; Linmarie Sikich, M.D.
Psychiatric Services 2013; doi: 10.1176/appi.ps.002762012
View Author and Article Information

Dr. Christian is affiliated with the Carolina Institute for Developmental Disabilities, CB 7255, Chapel Hill, NC 27599-7255 (e-mail: rob.christian@cidd.unc.edu). Dr. Christian is also with the Department of Psychiatry, University of North Carolina (UNC) Chapel Hill School of Medicine, Chapel Hill, where Dr. Sheitman, Dr. Barnhill, and Dr. Sikich are affiliated. Dr. Farley is with the UNC Eshelman School of Pharmacy, Chapel Hill, where Dr. Wei was formerly affiliated. Dr. Wei is now with North Carolina Community Care Networks, Raleigh, where Dr. McKee, Dr. Trygstad, and Dr. Pfeiffenberger are affiliated. Dr. Diamond is with the Department of Psychiatry, East Carolina University Brody School of Medicine, Greenville, North Carolina. Dr. Chrisman is with the Department of Psychiatry, Duke University School of Medicine, Durham, North Carolina. Dr. Lynn Wegner is with the UNC Department of Pediatrics, Chapel Hill. Dr. Palmes is with the Department of Psychiatry, Wake Forest University, Winston-Salem, North Carolina. Dr. Steven Wegner is with AccessCare North Carolina, Morrisville. Dr. Best is with the North Carolina Department of Medical Assistance, Raleigh.

Copyright © 2013 by the American Psychiatric Association

Objective  The rise in use of antipsychotics among U.S. children is well documented. Compliance rates with current safety-monitoring guidelines are low. In response, the North Carolina Division of Medical Assistance established the Antipsychotics—Keeping It Documented for Safety (A+KIDS) registry. The initial objectives of the project were to successfully establish a Web-based safety registry and to obtain and evaluate clinical information derived from the registry.

Methods  In April 2011, A+KIDS began asking prescribers of antipsychotics for children age 12 and under to respond to a set of questions regarding dose, indication, and usage history. Antipsychotic registrations were examined by linking North Carolina Medicaid prescription claims to registry entries. Prescribers were classified into different types, and the number of patients and registrations per prescriber were examined.

Results  In the initial six months, 730 prescribers registered 5,532 patients, 19% below age seven. By month 6 of the registry, 72% of all fills were registered with the program. Top diagnosis groups for registry patients were unspecified mood disorders, autism spectrum disorders, and disruptive behavior disorders. Top target symptoms were aggression (48%), irritability (19%), and impulsivity (11%). Psychosis accounted for 5% of the target symptoms. Twenty-eight percent of children were receiving no form of psychotherapy. Twenty-five percent of all A+KIDS prescribers were responsible for 81% of the registrations.

Conclusions  The A+KIDS registry initiative has been successful, as measured by rapid uptake, and is providing clinical information not available from claims data alone. Future efforts will allow for detailed examinations of antipsychotic utilization and further safety improvement.

Abstract Teaser
Figures in this Article

The dramatic rise in antipsychotic utilization among adolescents and children over the past two decades is well documented and has been an issue of particular concern to patients, families, pediatric health care prescribers, public and private payers, and policy makers (113). The rise is overwhelmingly accounted for by increased prescribing of second-generation antipsychotics despite known metabolic side effects, a lack of long-term effectiveness and safety data, and growing concerns about cost (513).

Multiple guidelines exist regarding safety monitoring for antipsychotics, yet rates of adherence to these guidelines are known to be poor (12,1416). In response, a novel Web-based registry was designed and implemented for medical providers serving child and adolescent North Carolina Medicaid recipients. This effort, A+KIDS (Antipsychotics—Keeping It Documented for Safety), is jointly funded by the North Carolina Division of Medical Assistance and Community Care Networks of North Carolina (CCNC), a statewide physician-driven, managed care collaborative (17). A more detailed history of the current North Carolina Medicaid antipsychotic policy, a comparison with other state policies on use of antipsychotics, and the development of the A+KIDS registry are discussed in a previously published Frontline Report (18), and general information about the program is available at www.documentforsafety.org.

During the initial implementation phase (April 12, 2011, through August 24, 2011), the registry asked all prescribers of first- or second-generation antipsychotics for children age 12 and under to provide responses to a brief set of clinical questions regarding the patient’s medication history, dose, and indications. [These questions and answers are available online in appendix A of the data supplement to this article.] Prescribers could have their initial interactions with the registry in several ways, including proactive registration of all current recipients of antipsychotic medication, with ongoing registration of medications at or near the time of writing the prescription, or a prescriber could be reminded by a pharmacy of the need to register. The initial registry information request was limited in scope to build provider comfort with the process. A fax option capturing the same information fields was allowed for prescribers who either had a preference for fax or limited Internet access. The only requirement for automated medication approval by the system was a minimum amount of data entry by the prescriber.

Unlike traditional prior-authorization programs, the A+KIDS system does not restrict access to medications based on protocols related to medication choice, dose, or indication. A+KIDS was designed to enhance patient safety by improving compliance with safety-monitoring recommendations, guiding prescribers through a decision-making process on risks and benefits of antipsychotic use, and providing a platform for the ongoing tracking of patient side effects that can be evaluated at the patient, provider, or drug level. The A+KIDS system operates in addition to standard pharmacy-level automated alerts regarding high dose, drug interactions, and therapeutic duplication. Pharmacy overrides are allowed to ensure that children are not denied access to prescribed medication, regardless of prescriber participation with the registry.

The statewide CCNC infrastructure was leveraged to engage community pharmacists and prescribers in a large-scale educational and registration initiative. Pharmacists were asked to contact prescribers to inform or remind them about the project and request their participation when overrides were required. A call center and help desk provided technical support. The next phase of implementation began August 24, 2011, and added questions on efficacy and side effects, including monitoring for metabolic and neurologic side effects. The registry prompts prescribers to update information every six months to maintain approval. [A timeline of key events and milestones is available online in appendix B of the data supplement.]

This report focuses on two objectives related to the development and implementation of A+KIDS in North Carolina over the initial six months, April 12, 2011, through October 12, 2011. These objectives included establishing a Web-based safety registry as determined by prescriber participation and demonstrating the ability of the registry to provide an enhanced understanding about the use of antipsychotics from patient-specific data not available from Medicaid claims data alone.

A+KIDS registry data and all Medicaid antipsychotic prescription claims for children age 12 and under were used to examine the initial six months of the registry. Patient, prescriber, and medication-level perspectives were used when analyzing registry information content.

We evaluated characteristics of registry patients age 12 and under from April 12 to October 12, 2011. We eliminated duplicate registrations of patients by using only the first registry entry per patient. Patient characteristics were stratified by younger (age six or younger) and older (seven to 12 years of age) child populations. We examined symptom characteristics and diagnostic characteristics associated with the first antipsychotic prescription entered into the A+KIDS system for that child. To reduce prescriber burden, A+KIDS allows for the provision of only one primary psychiatric diagnosis and one primary target symptom. However, the registry cannot prevent prescribers from entering multiple diagnoses or symptoms within write-in text fields or faxed forms. To account for these challenges, we developed a hierarchical classification of responses for primary diagnosis and primary target symptoms. [This scheme is described online in appendix C of the data supplement to this article.] Among the 5,532 patients in the registry, this process affected 276 (5%) diagnoses and 163 (3%) symptom classifications.

In addition, we also sought to characterize prescribers. Prescribers were classified according to their credentials in the National Plan and Prescriber Enumeration System (NPPES) as physician, nurse or nurse practitioner, physician assistant, or missing if the prescriber had no credential information in NPPES. Although providers were not queried directly on their subspecialty or area of practice, the interface queried about the first prescriber, whether the patient also had a psychiatrist, and whether the current prescriber was a psychiatrist. Across prescriber type, we examined the number of patients entered into the registry per prescriber, as well as the number of registrations per prescriber.

We examined registrations by linking Medicaid prescription claims to registry entries. Medicaid claims data were used to describe all prescription antipsychotic claims for patients age 12 and under in the Medicaid program from January 12, 2011, through October 11, 2011. For the purpose of evaluation of provider participation, a prescription was considered registered if it was filled or refilled after the A+KIDS registration for that medication was completed. Prescriptions were considered not registered if they were filled before medication registration or when no medication registrations were ever submitted for the medications. We examined the amount of antipsychotic claims that preceded entry of the information into the registry, at seven and 14 days after registry entry, and at any point more than 14 days after registration. Finally, we examined the number of total antipsychotic prescription claims paid monthly by Medicaid from April 12, 2011, to October 12, 2011, in relation to registered prescriptions over the same period.

+

Antipsychotic user characteristics

Characteristics of pediatric antipsychotic users as captured in the antipsychotic registry are shown in Table 1. A total of 5,532 unique patients were entered into the A+KIDS registry by prescribers. Eighty-one percent of patients were between the ages of seven and 12. Among this age group, 59% of antipsychotic users were non-Hispanic white and 29% of users were non-Hispanic black. More than 70% of pediatric antipsychotic users were male.

 
Anchor for Jump
Table 1Patient, prescriber, and treatment characteristics for children taking antipsychotic medication, by age groupa
Table Footer Note

a The highest-ranking diagnosis registration was used for instances of multiple registrations for the same patient. [The ranking scheme is available online in appendix C of the data supplement to this article.]

Table Footer Note

b Data are from the North Carolina Medicaid eligibility file. A total of 1,056 of the children ages ≤6 and 4,470 of those ages 7–12 were matched successfully to the registry (>99.9%).

Table Footer Note

c N=994 for the ≤6 population because of 66 nonresponses; N=4,219 for the 7–12 population because of 253 nonresponses.

Table Footer Note

d N=873 for the ≤6 population because of 187 nonresponses; N=3,801 for the 7–12 population because of 671 nonresponses.

Table Footer Note

e N=582 for the ≤6 population and N=2,778 for the 7–12 population

Table Footer Note

f Included paliperidone, asenapine, iloperidone, lurasidone, and olanzapine-fluoxetine

Table Footer Note

g Included chlorpromazine, haloperidol, pimozide, perphenazine, fluphenazine, trifluoperazine, and thioridazine

Table Footer Note

h Included paliperidone and risperidone

We examined a number of resource utilization features at the patient level. There were few apparent differences regarding resources being used by younger children versus older children. However, younger children were more likely than older children to have never used antipsychotics (24% versus 13%) and were less likely to have been taking the same antipsychotic for more than six months (38% versus 57%). A majority of prescribers seeing patients were psychiatrists, seeing 55% of the younger group and 63% of the older group. Further, most prescribers initiating antipsychotic treatment were outpatient psychiatrists; prescribers who were not psychiatrists initiated treatment with antipsychotic medication less often (28% and 19%) for patients ages six and under and for patients ages seven through 12, respectively. A small number of prescribers who were not psychiatrists indicated that patients saw a psychiatrist as well. A minority of patients saw other prescriber types, including nurse practitioners and physician assistant psychiatric specialty prescribers or developmental pediatricians.

Among patients ages six and under and those ages seven through 12, most were reported to be receiving psychotherapy. The most common types of psychotherapy among psychotherapy users were cognitive-behavioral or intensive in-home therapy. Prescribers did not know the type of psychotherapy being provided (22% and 23% of prescribers for younger and older children, respectively). The most common antipsychotic medications being used by patients in both age categories were risperidone, followed by aripiprazole and quetiapine. Few patients used other second-generation antipsychotic agents, first-generation antipsychotic agents, or long-acting injectable antipsychotics.

+

Antipsychotic prescriber characteristics

Table 2 describes the characteristics of prescribers using the A+KIDS registry. In the first six months of availability, the registry was used by 730 unique prescribers. A majority of these prescribers were physicians (73%), followed by nurse practitioners and nurses (15%) and physician assistants (8%). The mean number of patients entered into the registry per prescriber was 8.3, with a median of 2.0, whereas the mean number of unique registrations per prescriber (including duplicate registrations per patient for multiple medications) was 8.9, with a median of 3.0. Overall, there were 6,473 unique registrations, excluding duplicates from the same prescriber, for the same medication, or for the same patient. The top 10% of prescribers accounted for a majority (56%) of all antipsychotic registrations. The top 5% of prescribers accounted for 40% of registrations, with a mean of 66.4 registrations per provider in that subgroup over the six-month period.

 
Anchor for Jump
Table 2Characteristics of prescribers entering prescriptions in the first six months of the Antipsychotics—Keeping It Documented for Safety registry
Table Footer Note

a A patient was counted multiple times if he or she obtained registrations for the same medication from multiple prescribers (5,532 total patients versus 6,033 counts in the table).

Table Footer Note

b Repeat registrations were not excluded if a medication was previously registered for the same patient by other prescribers (6,072 unique registrations versus 6,473 counts in the table).

+

Antipsychotic indications

Table 3 is a cross-tabulation of reported primary diagnostic indications and primary target symptoms for registrations. The top four diagnosis groups included mood disorders (predominantly accounted for by unspecified mood disorders, affecting 64% [N=1,261] of the mood group), autism spectrum disorders and developmental disabilities, disruptive behavior disorders, and attention-deficit hyperactivity disorder. Aggression, irritability, and impulsivity were the highest-ranking target symptoms across these top four diagnostic groupings with few exceptions. One notable exception includes the target symptom of psychosis for schizophrenia and psychosis (81%). Overall, however, psychosis as a target symptom accounted for 5% of reported target symptoms.

 
Anchor for Jump
Table 3Target symptom being treated by antipsychotic medication across clinical diagnosis groupsa
Table Footer Note

a Based on symptoms and diagnoses for each of the 5,532 patients in A+KIDS (Antipsychotics—Keeping It Documented for Safety). For the purposes of illustration, 18 diagnoses were condensed into the eight listed diagnostic groups, mainly covering the following diagnoses: mood, for unspecified mood disorder, bipolar disorder, and depressive disorder; autism spectrum disorder or developmental disability, for autistic disorder, pervasive developmental disorder not otherwise specified, Asperger’s disorder, and developmental disability; disruptive behavior, for oppositional behavioral disorder, conduct disorder, and disruptive behavior disorder not otherwise specified; trauma, for posttraumatic stress disorder (PTSD) and reactive attachment disorder; psychosis and schizophrenia, for psychotic disorders and schizophrenia; anxiety, for any anxiety disorder except PTSD. Tourette’s and attention-deficit hyperactivity disorder did not encompass additional disorders.

Table Footer Note

b Percentages reflect totals for target symptoms across diagnostic groups, with 5,532 as the denominator.

+

Registry participation

We linked prescription claims data to the registry data and examined the time between registry entry and an antipsychotic claim. Figure 1 shows that 50% of antipsychotic prescription claims (fills) were registered in the seven days before prescription fill and that 59% of prescriptions were filled within 14 days of registration. More than 90% of prescriptions were filled at some point after the date of the registry entry. Of note, 5% of faxed registry entries and 6% of online registry entries had a prescription claim preceding the date of the registration, with no claims after this date. In addition, 2% of online and 1% of faxed registry entries had no prescription fills in the claims data associated with information collected through the registry process. Upon matching antipsychotic claims to A+KIDS entries, it was noted that by the sixth month of the registry, 72% of antipsychotic claims in the Medicaid program were matched to an A+KIDS registry entry (Figure 2). A majority of these registrations were entered using the online A+KIDS system, whereas 19% were matched to a faxed entry. Figure 2 also demonstrates that total monthly antipsychotic fills after launch of A+KIDS were never as high as in any month in the prior year.

 
Anchor for JumpAnchor for Jump
Figure 1Timeline of the number of antipsychotic fills surrounding A+KIDS medication registration datea

aA+KIDS, Antipsychotics—Keeping It Documented for Safety program; 74 (2%) and 21 (1%) A+KIDS registry entries were not accompanied by an antipsychotic fill before or after the medication was authorized online or via fax, respectively.

 
Anchor for JumpAnchor for Jump
Figure 2Antipsychotic prescription use among Medicaid pediatric patientsa

aPatients were ages 0–12. A prescription was considered registered if it was filled on or after the registration date of the medication. E-registered, online registration

+

Main findings

The North Carolina Division of Medical Assistance and CCNC implemented a Web-based registry to monitor the use of antipsychotic medications by children and adolescents in North Carolina. Within six months, most antipsychotic prescription fills were registered with A+KIDS and most prescriptions were filled within 14 days of registry entry. We used a relatively strict definition for registration for the purpose of analysis such that we may have artificially deflated registration rates. For example, if a child saw a prescriber and had the prescription filled the same day, before the prescriber was able to register the child, that fill would be counted as unregistered in the analysis. A very small minority of registrations were not matched to subsequent antipsychotic fills, implying that an antipsychotic medication was never filled or that a non-Medicaid source, such as private insurance, paid for the medication.

The relatively rapid prescriber uptake may be attributable to the large prelaunch prescriber education effort and to the campaign to engage other stakeholder groups such as mental health advocacy groups and the North Carolina Psychiatric Association. Ongoing outreach to providers was facilitated by a preexisting group of network pharmacists and psychiatrists associated with CCNC (17). Further, several features that separate A+KIDS from traditional prior-authorization programs may have improved participation: no restriction on the choice of medication, simple registration criteria, instantaneous approval, and interactive educational features. Future features, including more educational content, prescriber clinical and communication tools, and maintenance of certification credit hours tied to participation, may serve to enhance participation. Further enhancements will also allow providers to track patient information longitudinally and compare features of their patients and their prescribing with those of their peers. These enhancements are aimed to make the registry a more useful tool and to motivate compliance with prescribing and monitoring guidelines.

The initial findings presented in this report demonstrate the potential for a medication registry that captures clinical and utilization data not available from claims data alone. Several of the initial findings were provocative and raise significant questions about antipsychotic prescribing practice in North Carolina. For example, it is notable that a majority of registrations came from a minority of registered prescribers, suggesting highly varied practice styles or concentrated high-severity patient groups among certain prescribers or regions. Also, the data presented in Table 2 raise the possibility of differences in patients-per-provider and registration-per-provider rates between physicians and advanced practice medical professionals. The registry will need to mature before this question can be analyzed, but such future explorations of the role of subspecialty prescriber type and other practice-level factors in antipsychotic prescribing practice may help point the way to targeted provider education initiatives, targeted mental health resource allocation, and policy formation. There is also a preliminary suggestion that overall antipsychotic prescribing rates have dropped since A+KIDS implementation. A future, more detailed time-trend analysis is needed to verify this apparent trend, but if borne out, one could postulate a range of underlying mechanisms, from raised awareness regarding the risks of antipsychotics to the increased labor of registering that prescribers may now associate with prescribing this class of medications.

The clinical features of the group were notable in that aggression and irritability were among the top three target symptoms across nearly all diagnostic groupings. Unspecified mood disorder was the most common diagnostic group, which is notable because it is not a pull-down choice listed in the A+KIDS interface online and must be written in by prescribers. These findings are consistent with previous reports that the majority of antipsychotic prescribing to youths is off label. The validity of using off-label prescribing as a method for distinguishing non–evidence-based practice from evidence-based practice is often called into question by mental health clinicians. Of note, some psychotropic medications are used in the community and studied for years in open-label and small controlled trials before approval by the U.S. Food and Drug Administration is pursued or obtained. Given that off-label prescribing is so prevalent in child mental health and pediatric health care in general, this distinction may be far too blunt an instrument for determining approval in prior-authorization programs.

The findings reflected in Table 3 also demonstrate the difficulty of attaining diagnostic certainty in child mental health and the profound symptom overlap across childhood mental disorders. These findings may support the notion that symptom-based prescribing dominates over disorder-based specific treatment choices in child mental health. For example, aggression, although it may be a common associated feature, is not part of the DSM-IV criteria for any mood disorder, but aggression was overwhelmingly the top target symptom among children receiving an antipsychotic for a mood disorder.

+

Limitations

A+KIDS currently targets children covered by North Carolina Medicaid, potentially limiting generalizability of these findings. As the registry matures, we will be able to evaluate how the registry population compares with the Medicaid population and the North Carolina general population. The clinical information gathered by A+KIDS is entered by prescribers, many of whom may not be trained mental health diagnosticians. Further, the possibility exists that busy prescribers may allow support staff to enter data on their behalf. By design, A+KIDS allows only primary diagnostic and symptom-based indications. This feature may not allow prescribers to illustrate the complexity or severity of their patient’s illness but was deemed necessary for streamlining of the prescriber interface. These limitations are inherent trade-offs for gathering point-of-care–based information. With Medicaid claims linkage, medication and dosing information as well as components of diagnostic data are verifiable. However, diagnostic data, symptom data, and some components of medication usage history data cannot be verified without a detailed chart review and independently performed direct diagnostic patient evaluation.

Medication adherence assessment is an inherent challenge in this large-scale initiative, but prescription claims data analysis techniques are able to reliably estimate adherence (19). The use of biologic metrics of adherence among subgroups of patients may further strengthen the findings of future work. Future analyses will require further linkage to claims data and will focus on several areas, including validation studies of prescriber-entered data, the evaluation of resource utilization and behavioral health consequences resulting from registry implementation, evaluation of polypharmacy rates and patterns, detailed evaluations of relationships between antipsychotic usage rates and prescriber subtypes, detailed descriptions and analysis of obesity rates among registrants, and the ongoing evaluation of the ability of the registry to influence prescribing trends over time.

The A+KIDS registry was successfully implemented with a high rate of user uptake. It has demonstrated its ability to capture clinical information not available from claims data alone and illustrated its potential to point out provocative features of psychotropic prescribing patterns in North Carolina. The A+KIDS registry has demonstrated initial viability as an alternative to traditional prior-authorization programs. With increasing prescriber usage, the addition of the adolescent cohort, metabolic data collection, and enhanced educational features, the registry is poised to fulfill its longer-term objectives of improving compliance with evidence-based prescribing and safety-monitoring guidelines.

This work was funded through a contract with AccessCare North Carolina.

Dr. Farley has been a consultant to Novartis and Daiichi-Sankyo. Dr. Sikich has received research funding in the past three years from or participates in clinical trials sponsored by Bristol-Myers Squibb, Curemark, Merck, Forest, Otsuka Research Institute, SynapDx, and Seaside Pharmaceuticals, and she has received software for a computer intervention in schizophrenia from Posit Science. The other authors report no competing interests.

Constantine  R;  Tandon  R:  Changing trends in pediatric antipsychotic use in Florida’s Medicaid program.  Psychiatric Services 59:1162–1168, 2008
[CrossRef] | [PubMed]
 
Cooper  WO;  Hickson  GB;  Fuchs  C  et al:  New users of antipsychotic medications among children enrolled in TennCare.  Archives of Pediatrics and Adolescent Medicine 158:753–759, 2004
[CrossRef] | [PubMed]
 
Cooper  WO;  Arbogast  PG;  Ding  H  et al:  Trends in prescribing of antipsychotic medications for US children.  Ambulatory Pediatrics 6:79–83, 2006
[CrossRef] | [PubMed]
 
Curtis  LH;  Masselink  LE;  Østbye  T  et al:  Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States.  Archives of Pediatrics and Adolescent Medicine 159:362–366, 2005
[CrossRef] | [PubMed]
 
Domino  ME;  Swartz  MS:  Who are the new users of antipsychotic medications? Psychiatric Services 59:507–514, 2008
[CrossRef] | [PubMed]
 
Olfson  M;  Marcus  SC;  Weissman  MM  et al:  National trends in the use of psychotropic medications by children.  Journal of the American Academy of Child and Adolescent Psychiatry 41:514–521, 2002
[CrossRef] | [PubMed]
 
Olfson  M;  Crystal  S;  Huang  C  et al:  Trends in antipsychotic drug use by very young, privately insured children.  Journal of the American Academy of Child and Adolescent Psychiatry 49:13–23, 2010
[PubMed]
 
Olfson  M;  Blanco  C;  Liu  L  et al:  National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.  Archives of General Psychiatry 63:679–685, 2006
[CrossRef] | [PubMed]
 
Patel  NC;  Sanchez  RJ;  Johnsrud  MT  et al:  Trends in antipsychotic use in a Texas Medicaid population of children and adolescents: 1996 to 2000.  Journal of Child and Adolescent Psychopharmacology 12:221–229, 2002
[CrossRef] | [PubMed]
 
Patel  NC;  Crismon  ML;  Hoagwood  K  et al:  Trends in the use of typical and atypical antipsychotics in children and adolescents.  Journal of the American Academy of Child and Adolescent Psychiatry 44:548–556, 2005
[CrossRef] | [PubMed]
 
Verdoux  H;  Tournier  M;  Bégaud  B:  Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies.  Acta Psychiatrica Scandinavica 121:4–10, 2010
[CrossRef] | [PubMed]
 
Medicaid Medical Directors Learning Network and Rutgers Center for Education and Research on Mental Health Therapeutics: Antipsychotic Medication Use in Medicaid Children and Adolescents: Report and Resource Guide From a 16-State Study. New Brunswick, NJ, Rutgers Institute for Health, Health Care Policy and Aging Research, July 2010
 
Lieberman  JA:  Comparative effectiveness of antipsychotic drugs: a commentary on: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).  Archives of General Psychiatry 63:1069–1072, 2006
[CrossRef] | [PubMed]
 
American Academy of Child and Adolescent Psychiatry:  Practice parameter on the use of psychotropic medication in children and adolescents.  Journal of the American Academy of Child and Adolescent Psychiatry 48:961–973, 2009
[CrossRef] | [PubMed]
 
Correll  CU;  Penzner  JB;  Parikh  UH  et al:  Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents.  Child and Adolescent Psychiatric Clinics of North America 15:177–206, 2006
[CrossRef] | [PubMed]
 
Sernyak  MJ:  Implementation of monitoring and management guidelines for second-generation antipsychotics.  Journal of Clinical Psychiatry 68(suppl 4):14–18, 2007
[CrossRef] | [PubMed]
 
Steiner  BD;  Denham  AC;  Ashkin  E  et al:  Community Care of North Carolina: improving care through community health networks.  Annals of Family Medicine 6:361–367, 2008
[CrossRef] | [PubMed]
 
Farley  JF;  Weeks  L;  Wegner  SE:  The A+KIDS program.  Psychiatric Services 64:98–99, 2013
[CrossRef] | [PubMed]
 
Hansen  RA;  Kim  MM;  Song  L  et al:  Comparison of methods to assess medication adherence and classify nonadherence.  Annals of Pharmacotherapy 43:413–422, 2009
[CrossRef] | [PubMed]
 
References Container

Figure 1 Timeline of the number of antipsychotic fills surrounding A+KIDS medication registration datea

aA+KIDS, Antipsychotics—Keeping It Documented for Safety program; 74 (2%) and 21 (1%) A+KIDS registry entries were not accompanied by an antipsychotic fill before or after the medication was authorized online or via fax, respectively.

Figure 2 Antipsychotic prescription use among Medicaid pediatric patientsa

aPatients were ages 0–12. A prescription was considered registered if it was filled on or after the registration date of the medication. E-registered, online registration

Anchor for Jump
Table 1Patient, prescriber, and treatment characteristics for children taking antipsychotic medication, by age groupa
Table Footer Note

a The highest-ranking diagnosis registration was used for instances of multiple registrations for the same patient. [The ranking scheme is available online in appendix C of the data supplement to this article.]

Table Footer Note

b Data are from the North Carolina Medicaid eligibility file. A total of 1,056 of the children ages ≤6 and 4,470 of those ages 7–12 were matched successfully to the registry (>99.9%).

Table Footer Note

c N=994 for the ≤6 population because of 66 nonresponses; N=4,219 for the 7–12 population because of 253 nonresponses.

Table Footer Note

d N=873 for the ≤6 population because of 187 nonresponses; N=3,801 for the 7–12 population because of 671 nonresponses.

Table Footer Note

e N=582 for the ≤6 population and N=2,778 for the 7–12 population

Table Footer Note

f Included paliperidone, asenapine, iloperidone, lurasidone, and olanzapine-fluoxetine

Table Footer Note

g Included chlorpromazine, haloperidol, pimozide, perphenazine, fluphenazine, trifluoperazine, and thioridazine

Table Footer Note

h Included paliperidone and risperidone

Anchor for Jump
Table 2Characteristics of prescribers entering prescriptions in the first six months of the Antipsychotics—Keeping It Documented for Safety registry
Table Footer Note

a A patient was counted multiple times if he or she obtained registrations for the same medication from multiple prescribers (5,532 total patients versus 6,033 counts in the table).

Table Footer Note

b Repeat registrations were not excluded if a medication was previously registered for the same patient by other prescribers (6,072 unique registrations versus 6,473 counts in the table).

Anchor for Jump
Table 3Target symptom being treated by antipsychotic medication across clinical diagnosis groupsa
Table Footer Note

a Based on symptoms and diagnoses for each of the 5,532 patients in A+KIDS (Antipsychotics—Keeping It Documented for Safety). For the purposes of illustration, 18 diagnoses were condensed into the eight listed diagnostic groups, mainly covering the following diagnoses: mood, for unspecified mood disorder, bipolar disorder, and depressive disorder; autism spectrum disorder or developmental disability, for autistic disorder, pervasive developmental disorder not otherwise specified, Asperger’s disorder, and developmental disability; disruptive behavior, for oppositional behavioral disorder, conduct disorder, and disruptive behavior disorder not otherwise specified; trauma, for posttraumatic stress disorder (PTSD) and reactive attachment disorder; psychosis and schizophrenia, for psychotic disorders and schizophrenia; anxiety, for any anxiety disorder except PTSD. Tourette’s and attention-deficit hyperactivity disorder did not encompass additional disorders.

Table Footer Note

b Percentages reflect totals for target symptoms across diagnostic groups, with 5,532 as the denominator.

+

References

Constantine  R;  Tandon  R:  Changing trends in pediatric antipsychotic use in Florida’s Medicaid program.  Psychiatric Services 59:1162–1168, 2008
[CrossRef] | [PubMed]
 
Cooper  WO;  Hickson  GB;  Fuchs  C  et al:  New users of antipsychotic medications among children enrolled in TennCare.  Archives of Pediatrics and Adolescent Medicine 158:753–759, 2004
[CrossRef] | [PubMed]
 
Cooper  WO;  Arbogast  PG;  Ding  H  et al:  Trends in prescribing of antipsychotic medications for US children.  Ambulatory Pediatrics 6:79–83, 2006
[CrossRef] | [PubMed]
 
Curtis  LH;  Masselink  LE;  Østbye  T  et al:  Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States.  Archives of Pediatrics and Adolescent Medicine 159:362–366, 2005
[CrossRef] | [PubMed]
 
Domino  ME;  Swartz  MS:  Who are the new users of antipsychotic medications? Psychiatric Services 59:507–514, 2008
[CrossRef] | [PubMed]
 
Olfson  M;  Marcus  SC;  Weissman  MM  et al:  National trends in the use of psychotropic medications by children.  Journal of the American Academy of Child and Adolescent Psychiatry 41:514–521, 2002
[CrossRef] | [PubMed]
 
Olfson  M;  Crystal  S;  Huang  C  et al:  Trends in antipsychotic drug use by very young, privately insured children.  Journal of the American Academy of Child and Adolescent Psychiatry 49:13–23, 2010
[PubMed]
 
Olfson  M;  Blanco  C;  Liu  L  et al:  National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.  Archives of General Psychiatry 63:679–685, 2006
[CrossRef] | [PubMed]
 
Patel  NC;  Sanchez  RJ;  Johnsrud  MT  et al:  Trends in antipsychotic use in a Texas Medicaid population of children and adolescents: 1996 to 2000.  Journal of Child and Adolescent Psychopharmacology 12:221–229, 2002
[CrossRef] | [PubMed]
 
Patel  NC;  Crismon  ML;  Hoagwood  K  et al:  Trends in the use of typical and atypical antipsychotics in children and adolescents.  Journal of the American Academy of Child and Adolescent Psychiatry 44:548–556, 2005
[CrossRef] | [PubMed]
 
Verdoux  H;  Tournier  M;  Bégaud  B:  Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies.  Acta Psychiatrica Scandinavica 121:4–10, 2010
[CrossRef] | [PubMed]
 
Medicaid Medical Directors Learning Network and Rutgers Center for Education and Research on Mental Health Therapeutics: Antipsychotic Medication Use in Medicaid Children and Adolescents: Report and Resource Guide From a 16-State Study. New Brunswick, NJ, Rutgers Institute for Health, Health Care Policy and Aging Research, July 2010
 
Lieberman  JA:  Comparative effectiveness of antipsychotic drugs: a commentary on: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).  Archives of General Psychiatry 63:1069–1072, 2006
[CrossRef] | [PubMed]
 
American Academy of Child and Adolescent Psychiatry:  Practice parameter on the use of psychotropic medication in children and adolescents.  Journal of the American Academy of Child and Adolescent Psychiatry 48:961–973, 2009
[CrossRef] | [PubMed]
 
Correll  CU;  Penzner  JB;  Parikh  UH  et al:  Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents.  Child and Adolescent Psychiatric Clinics of North America 15:177–206, 2006
[CrossRef] | [PubMed]
 
Sernyak  MJ:  Implementation of monitoring and management guidelines for second-generation antipsychotics.  Journal of Clinical Psychiatry 68(suppl 4):14–18, 2007
[CrossRef] | [PubMed]
 
Steiner  BD;  Denham  AC;  Ashkin  E  et al:  Community Care of North Carolina: improving care through community health networks.  Annals of Family Medicine 6:361–367, 2008
[CrossRef] | [PubMed]
 
Farley  JF;  Weeks  L;  Wegner  SE:  The A+KIDS program.  Psychiatric Services 64:98–99, 2013
[CrossRef] | [PubMed]
 
Hansen  RA;  Kim  MM;  Song  L  et al:  Comparison of methods to assess medication adherence and classify nonadherence.  Annals of Pharmacotherapy 43:413–422, 2009
[CrossRef] | [PubMed]
 
References Container
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Articles
Books
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 1.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 4.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 4.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 4.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 4.  >
Topic Collections
Psychiatric News
Read more at Psychiatric News >>
APA Guidelines
PubMed Articles